Home > Insider Trading > Filing (0001209191-14-009634)

Filing Details

Accession Number:: 0001209191-14-009634
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-02-12 16:01:20
Reporting Period:: 2014-02-10

Filing Date:: 2014-02-12
Accepted Time:: 2014-02-12 16:01:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1338042	Aegerion Pharmaceuticals Inc.	AEGR	Pharmaceutical Preparations (2834)	202960116

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1520265	J. Mark Fitzpatrick	C/O Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-02-10	7,500	$17.64	13,350	No	4	M	Direct
Common Stock	Disposition	2014-02-10	3,300	$61.71	10,050	No	4	S	Direct
Common Stock	Disposition	2014-02-10	2,814	$62.94	7,236	No	4	S	Direct
Common Stock	Disposition	2014-02-10	900	$63.72	6,336	No	4	S	Direct
Common Stock	Disposition	2014-02-10	486	$64.69	5,850	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2014-02-10	7,500	$0.00	7,500	$17.64

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
192,150		2021-06-01	No	4	M	Direct

Footnotes

The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Plan"). The Plan was adopted for purposes of investment portfolio diversification.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.295 to $62.26, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.37 to $63.35, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.38 to $64.17, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.61 to $64.90, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
132,000 of the shares of common stock underlying this stock option vest over four years in equal monthly installments starting on June 1, 2011. 88,000 of the shares of common stock underlying this stock option vest over four years in equal monthly installments starting on the date of marketing approval for JUXTAPID TM (lomitapide) by the U.S. Food and Drug Administration.